Pub Date : 2021-06-23DOI: 10.19070/2332-290x-2100093
Soumya Harapanahalli Venkatesh
{"title":"Epidemiological and Clinical Profile Of Fever Related Retinitis: A Hospital Based Study","authors":"Soumya Harapanahalli Venkatesh","doi":"10.19070/2332-290x-2100093","DOIUrl":"https://doi.org/10.19070/2332-290x-2100093","url":null,"abstract":"","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42904061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-12DOI: 10.19070/2332-290X-2100091
Alnoelaty ALmasri M.A
Current present-day cataract surgery evolves from a visual restoration to a refractive approach. Greater independence from glasses and improvement of the quality of life were provided after surgery with the appearance of multifocal intraocular lenses (MF-IOLs). Since its creation in the 1980s, MFIOLs has undergone various technical improvements, including trifocal implants and implants with extended depth of vision. Excellent results were achieved thorough preoperative check, including the visual needs of the patients and the inherent eye anatomy. This analysis offers a broad overview of the various types of Mf-IOLs and rules for optimizing results through full preoperative screening and treatment postoperatively complications.
{"title":"Optimizing Outcomes with Multifocal Intraocular Lenses","authors":"Alnoelaty ALmasri M.A","doi":"10.19070/2332-290X-2100091","DOIUrl":"https://doi.org/10.19070/2332-290X-2100091","url":null,"abstract":"Current present-day cataract surgery evolves from a visual restoration to a refractive approach. Greater independence from glasses and improvement of the quality of life were provided after surgery with the appearance of multifocal intraocular lenses (MF-IOLs). Since its creation in the 1980s, MFIOLs has undergone various technical improvements, including trifocal implants and implants with extended depth of vision. Excellent results were achieved thorough preoperative check, including the visual needs of the patients and the inherent eye anatomy. This analysis offers a broad overview of the various types of Mf-IOLs and rules for optimizing results through full preoperative screening and treatment postoperatively complications.","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48182471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.19070/2332-290x-2100095
Nur Rizqillah
{"title":"The Role of Diabetes Mellitus in Causing Posterior Subcapsular Cataracts in Outpatients (Case From Indonesian Eye Hospital)","authors":"Nur Rizqillah","doi":"10.19070/2332-290x-2100095","DOIUrl":"https://doi.org/10.19070/2332-290x-2100095","url":null,"abstract":"","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41599430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-02DOI: 10.19070/2332-290X-1900081
H. Kauser, R. Garg
Inflammation or infection of the conjunctiva is known as conjunctivitis. It is characterized by dilatation of conjunctival vessels, hyperemia and edema of the conjunctiva and typically associated with discharge [1]. Conjunctivitis affects many people and imposes economic burden. Approximately 6 million people were affected annually with acute conjunctivitis in the United States [2]. The cost of treating bacterial conjunctivitis alone was estimated to be $377 million to $857 million per year [3]. Irrespective of the cause of conjunctivitis, in many US state health departments, students are required to be treated with topical antibiotic eye drops before returning to school [4].
{"title":"Do Ophthalmologists in India Over Prescribing Topical Antibiotics in Acute Infectious Conjunctivitis?","authors":"H. Kauser, R. Garg","doi":"10.19070/2332-290X-1900081","DOIUrl":"https://doi.org/10.19070/2332-290X-1900081","url":null,"abstract":"Inflammation or infection of the conjunctiva is known as conjunctivitis. It is characterized by dilatation of conjunctival vessels, hyperemia and edema of the conjunctiva and typically associated with discharge [1]. Conjunctivitis affects many people and imposes economic burden. Approximately 6 million people were affected annually with acute conjunctivitis in the United States [2]. The cost of treating bacterial conjunctivitis alone was estimated to be $377 million to $857 million per year [3]. Irrespective of the cause of conjunctivitis, in many US state health departments, students are required to be treated with topical antibiotic eye drops before returning to school [4].","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42199393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-09DOI: 10.19070/2332-290X-1900080
Filali C.
Chondroid syringoma is a rare mixed tumor accounting for only 0.01% of all primary skin tumors [1]. Though it’s very common occurrence is in head and the neck region, involvement of eyelids is extremely rare [2]. These are usually a slowly growing, asymptomatic, solitary, non ulcerating masses ranging between 0.5cm and 3.0cm in size [2]. Herein we report another rare case of chondroid syringoma of eyebrow in a young man.
{"title":"Unusual Lesion of the Eyebrow: A Case Report of Chondroid Syringoma","authors":"Filali C.","doi":"10.19070/2332-290X-1900080","DOIUrl":"https://doi.org/10.19070/2332-290X-1900080","url":null,"abstract":"Chondroid syringoma is a rare mixed tumor accounting for only 0.01% of all primary skin tumors [1]. Though it’s very common occurrence is in head and the neck region, involvement of eyelids is extremely rare [2]. These are usually a slowly growing, asymptomatic, solitary, non ulcerating masses ranging between 0.5cm and 3.0cm in size [2]. Herein we report another rare case of chondroid syringoma of eyebrow in a young man.","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42404227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-31DOI: 10.19070/2332-290x-1800079
Anita T Girish, Soumya Hv, A. Singal
1 DOMS, DNB, Associate Professor, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 2 MS, Associate Professor, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 3 MS, Junior Resident, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 4 DOMS, Junior Resident, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India.
{"title":"Manual Small Incisional Cataract Surgery Learning Curve: Observational Comparison of Three Trainee Training","authors":"Anita T Girish, Soumya Hv, A. Singal","doi":"10.19070/2332-290x-1800079","DOIUrl":"https://doi.org/10.19070/2332-290x-1800079","url":null,"abstract":"1 DOMS, DNB, Associate Professor, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 2 MS, Associate Professor, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 3 MS, Junior Resident, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India. 4 DOMS, Junior Resident, Department of Ophthalmology, JSS Medical College and Hospital, Mysore, Karnataka, India.","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41800343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-13DOI: 10.19070/2332-290X-1800077
A. Gupta, Verma Ak
{"title":"Management of Recurrent Pterygium - A Case Report","authors":"A. Gupta, Verma Ak","doi":"10.19070/2332-290X-1800077","DOIUrl":"https://doi.org/10.19070/2332-290X-1800077","url":null,"abstract":"","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47776475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.19070/2332-290X-1800076
S. Sharma, K. Ma, A. Chaturvedi
Purpose: To evaluate the effectiveness of Razumab^® (world's first biosimilar ranibizumab; Intas Pharmaceuticals Ltd., India) in Indian patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Methods: RE-ENACT, a retrospective, multicenter study, analyzed pooled data of patients with wet AMD, DME, and RVO. Patients who had received ≥3 injections of Razumab^® between January and August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/Snellen's chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography), and proportion of patients with intraretinal fluid (IRF) and subretinal fluid (SRF) at Weeks 4, 8 and 12. Results: Of 561 patients included, 348 (62.04%) were men. Mean ± SE BCVA improved from baseline (0.75 ± 0.01) to Week 4 (0.72 ± 0.01, p = 0.0318), attained significance at Week 8 (0.59 ± 0.01, p ＜ 0.0001), which was maintained at Week 12 (0.49 ± 0.01, p ＜ 0.0001). Mean ± SE CMT significantly (p ＜ 0.0001) decreased from baseline (418.47 ± 4.78μm) to Weeks 4 (407.35 ± 4.65μm), 8 (342.10 ± 3.66μm), and 12 (301.17 ± 2.82μm). Proportion of patients with IRF and SRF significantly (p ＜ 0.0001) decreased from baseline to Weeks 4, 8 and 12 (67.02% vs. 48.48%, 42.60%, and 34.22%, respectively for IRF; and 72.37% vs. 48.48%, 37.97%, 31.37%, respectively for SRF). No new safety concerns with biosimilar ranibizumab were observed. Conclusions: Razumab^® is effective in reducing macular thickness and improving visual acuity in patients with wet agerelated macular degeneration, diabetic macular edema, and retinal vein occlusion in routine clinical practice. Razumab^® demonstrated considerable effectiveness with no new safety concerns.
目的:评价Razumab^®(世界首个生物仿制药雷尼单抗;Intas制药有限公司，印度)在印度患者湿性年龄相关性黄斑变性(湿性AMD)，糖尿病性黄斑水肿(DME)和视网膜静脉闭塞(RVO)。方法:RE-ENACT是一项回顾性、多中心研究，分析了湿性AMD、DME和RVO患者的汇总数据。在2016年1月至8月期间接受≥3次Razumab^®注射的患者被纳入研究。终点是:最佳矫正视力(BCVA，通过logMAR/Snellen’s图测量)的改善，中央黄斑厚度(CMT，通过光谱域光学相干断层扫描测量)的减少，以及在第4,8和12周时视网膜内液(IRF)和视网膜下液(SRF)患者的比例。结果:561例患者中，男性348例(62.04%)。平均±SE BCVA从基线(0.75±0.01)改善到第4周(0.72±0.01,p = 0.0318)，在第8周达到显著性(0.59±0.01,p < 0.0001)，在第12周保持显著性(0.49±0.01,p < 0.0001)。从基线(418.47±4.78μm)到第4周(407.35±4.65μm)、第8周(342.10±3.66μm)和第12周(301.17±2.82μm)， Mean±SE CMT显著(p < 0.0001)下降。从基线到第4,8和12周，IRF和SRF患者比例显著(p < 0.0001)下降(67.02% vs. 48.48%， 42.60%和34.22%);72.37% vs. SRF分别为48.48%，37.97%，31.37%)。未观察到雷尼单抗生物仿制药的新的安全性问题。结论:在常规临床实践中，Razumab^®可有效降低湿相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉闭塞患者的黄斑厚度和改善视力。Razumab^®显示出相当大的有效性，没有新的安全性问题。
{"title":"Real-Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age- Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Retrospective Pooled Analysis","authors":"S. Sharma, K. Ma, A. Chaturvedi","doi":"10.19070/2332-290X-1800076","DOIUrl":"https://doi.org/10.19070/2332-290X-1800076","url":null,"abstract":"Purpose: To evaluate the effectiveness of Razumab^® (world's first biosimilar ranibizumab; Intas Pharmaceuticals Ltd., India) in Indian patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Methods: RE-ENACT, a retrospective, multicenter study, analyzed pooled data of patients with wet AMD, DME, and RVO. Patients who had received ≥3 injections of Razumab^® between January and August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/Snellen's chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography), and proportion of patients with intraretinal fluid (IRF) and subretinal fluid (SRF) at Weeks 4, 8 and 12. Results: Of 561 patients included, 348 (62.04%) were men. Mean ± SE BCVA improved from baseline (0.75 ± 0.01) to Week 4 (0.72 ± 0.01, p = 0.0318), attained significance at Week 8 (0.59 ± 0.01, p ＜ 0.0001), which was maintained at Week 12 (0.49 ± 0.01, p ＜ 0.0001). Mean ± SE CMT significantly (p ＜ 0.0001) decreased from baseline (418.47 ± 4.78μm) to Weeks 4 (407.35 ± 4.65μm), 8 (342.10 ± 3.66μm), and 12 (301.17 ± 2.82μm). Proportion of patients with IRF and SRF significantly (p ＜ 0.0001) decreased from baseline to Weeks 4, 8 and 12 (67.02% vs. 48.48%, 42.60%, and 34.22%, respectively for IRF; and 72.37% vs. 48.48%, 37.97%, 31.37%, respectively for SRF). No new safety concerns with biosimilar ranibizumab were observed. Conclusions: Razumab^® is effective in reducing macular thickness and improving visual acuity in patients with wet agerelated macular degeneration, diabetic macular edema, and retinal vein occlusion in routine clinical practice. Razumab^® demonstrated considerable effectiveness with no new safety concerns.","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44358628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-02-15DOI: 10.19070/2332-290X-1600037
Vellanki S, Ferrigno A, Alanis Y, Betts-Obregon Bs, Tsin At
PURPOSE Diabetic retinopathy is manifested by excessive angiogenesis and high level of vascular endothelial growth factor (VEGF) in the eye. METHODS Human (MIO-M1) and rat (rMC-1) Müller cells were treated with 0, 5.5, or 30mM glucose for 24 hours. Viable cell counts were obtained by Trypan Blue Dye Exclusion Method. ELISA was used to determine VEGF levels in cell medium. RESULTS Compared to 24 hour treatment by 5.5mM glucose, MIO-M1 and rMC-1 in 30mM glucose increased in viable cell number by 38% and 24% respectively. In contrast, viable cells in 0mM glucose decreased by 28% and 50% respectively. Compared to 5.5mM, MIO-M1 and rMC-1 in 30mM glucose had increased levels of VEGF in cell medium (pg/ml by 24% and 20%) and also VEGF concentration in cells held in 0mM increased by 47% and 10% respectively. In both MIO-M1 and rMC-1, the amount of VEGF secreted per cell increased by about 100% when glucose was changed from 5.5 to 0mM but decreased slightly (17% in MIO-M1 and 11% in rMC-1) when glucose was increased from 5.5 to 30mM. CONCLUSIONS Our results show that MIO-M1 and rMC-1 are highly responsive to changes in glucose concentrations. 30mM compared to 5.5mM significantly increased cell viability but induced a significant change in VEGF secretion per cell in rMC-1 only. At 0, 5.5, and 30mM glucose, MIO-M1 secreted about 5-7-fold higher level of VEGF (pg/cell) than rMC-1. The mechanism of glucose-induced changes in rMC-1 and MIO-M1 cell viability and VEGF secretion remains to be elucidated.
{"title":"High Glucose and Glucose Deprivation Modulate Müller Cell Viability and VEGF Secretion.","authors":"Vellanki S, Ferrigno A, Alanis Y, Betts-Obregon Bs, Tsin At","doi":"10.19070/2332-290X-1600037","DOIUrl":"https://doi.org/10.19070/2332-290X-1600037","url":null,"abstract":"PURPOSE\u0000Diabetic retinopathy is manifested by excessive angiogenesis and high level of vascular endothelial growth factor (VEGF) in the eye.\u0000\u0000\u0000METHODS\u0000Human (MIO-M1) and rat (rMC-1) Müller cells were treated with 0, 5.5, or 30mM glucose for 24 hours. Viable cell counts were obtained by Trypan Blue Dye Exclusion Method. ELISA was used to determine VEGF levels in cell medium.\u0000\u0000\u0000RESULTS\u0000Compared to 24 hour treatment by 5.5mM glucose, MIO-M1 and rMC-1 in 30mM glucose increased in viable cell number by 38% and 24% respectively. In contrast, viable cells in 0mM glucose decreased by 28% and 50% respectively. Compared to 5.5mM, MIO-M1 and rMC-1 in 30mM glucose had increased levels of VEGF in cell medium (pg/ml by 24% and 20%) and also VEGF concentration in cells held in 0mM increased by 47% and 10% respectively. In both MIO-M1 and rMC-1, the amount of VEGF secreted per cell increased by about 100% when glucose was changed from 5.5 to 0mM but decreased slightly (17% in MIO-M1 and 11% in rMC-1) when glucose was increased from 5.5 to 30mM.\u0000\u0000\u0000CONCLUSIONS\u0000Our results show that MIO-M1 and rMC-1 are highly responsive to changes in glucose concentrations. 30mM compared to 5.5mM significantly increased cell viability but induced a significant change in VEGF secretion per cell in rMC-1 only. At 0, 5.5, and 30mM glucose, MIO-M1 secreted about 5-7-fold higher level of VEGF (pg/cell) than rMC-1. The mechanism of glucose-induced changes in rMC-1 and MIO-M1 cell viability and VEGF secretion remains to be elucidated.","PeriodicalId":90865,"journal":{"name":"International journal of ophthalmology & eye science","volume":"4 2 1","pages":"178-183"},"PeriodicalIF":0.0,"publicationDate":"2016-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68341468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：